Dr. Chagpar on Surgery of the Primary Tumor in Metastatic Breast Cancer

Video

In Partnership With:

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses surgery of the primary tumor in the metastatic setting of breast cancer.

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses surgery of the primary tumor in the metastatic setting of breast cancer.

Distant metastatic disease has often been a contraindication for surgery of the primary tumor. The goal of surgery is to render these patients as no evidence of disease, but it is said that this cannot be done with distant metastatic spread, Chagpar explains.

Two randomized controlled trials have investigated whether surgery of the primary tumor can improve survival. However, the findings have been mixed. One trial from India showed that there was no survival benefit with the addition of surgery. A trial out of Turkey showed that there was, but this may be due to differences in the designs of these trials, Chagpar says. Ultimately, Chagpar says that findings from ongoing trials will be the determining factors on this debate.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute